SOFTMEDX-NEW (00648) has released its interim results for 2026, posting a net profit of HK$4.648 million, a 38.62% increase compared to the same period last year.

Revenue for the period reached HK$34.075 million, reflecting a 4.74% decline year-on-year. Earnings per share stood at HK4.4 cents.

The company attributed the profit growth to a reduction in administrative expenses and the absence of losses from changes in fair value of financial assets measured at fair value through profit or loss.